Novel hydroxysteroid (17β) dehydrogenase 1 inhibitors reverse estrogen-induced endometrial hyperplasia in transgenic mice

American Journal of Pathology

Volumn 176, Issue 3, 2010, Pages 1443-1451

  Saloniemi, Taija ^a   Järvensivu, Päivi ^a   Koskimies, Pasi ^b   Jokela, Heli ^a   Lamminen, Tarja ^a   Ghaem Maghami, Sadaf ^c   Dina, Roberto ^c   Damdimopoulou, Pauliina ^a   Mäkelä, Sari ^a   Perheentupa, Antti ^a,e   Kujari, Harry ^a   Brosens, Jan ^d   Poutanen, Matti ^a,f  

^a UNIVERSITY OF TURKU   (Finland)

^b Hormos Medical Ltd Subsidiary of QuatRx Pharmaceuticals   (Finland)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e TURKU UNIVERSITY HOSPITAL   (Finland)

^f Turku Center for Disease Modeling   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

MEDROXYPROGESTERONE ACETATE; PROGESTERONE; TESTOSTERONE 17BETA DEHYDROGENASE; 3 (OR 17) BETA HYDROXYSTEROID DEHYDROGENASE; 3 (OR 17)-BETA-HYDROXYSTEROID DEHYDROGENASE; ENZYME INHIBITOR; ESTRADIOL; ESTROGEN; GESTAGEN; HYDROXYSTEROID DEHYDROGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOMETRIUM HYPERPLASIA; FEMALE; MOUSE; NONHUMAN; OVULATION INDUCTION; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GROWTH, DEVELOPMENT AND AGING; HUMAN; METABOLISM; ORGAN SIZE; PATHOLOGY; TRANSGENIC MOUSE; UTERUS;

17-HYDROXYSTEROID DEHYDROGENASES; ANIMALS; DISEASE MODELS, ANIMAL; ENDOMETRIAL HYPERPLASIA; ENZYME INHIBITORS; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; MICE; MICE, TRANSGENIC; ORGAN SIZE; PROGESTINS; UTERUS;

EID: 77749245862     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.090325     Document Type: Article

References (68)

1. Eskenazi B, Warner ML: Epidemiology of endometriosis. Obstet Gynecol Clin North Am 1997, 24:235-258
2. Dassen H, Punyadeera C, Kamps R, Delvoux B, Van Langendonckt A, Donnez J, Husen B, Thole H, Dunselman G, Groothuis P: Estrogen metabolizing enzymes in endometrium and endometriosis. Hum Reprod 2007, 22:3148-3158
3. Kurman R: Blaustein's pathology of the female genital tract. New York, Springer-Verlag, 2002:467-559
4. Smuc T, Rupreht R, Sinkovec J, Adamski J, Rizner TL: Expression analysis of estrogen-metabolizing enzymes in human endometrial cancer. Mol Cell Endocrinol 2006, 248:114-117
5. Horn LC, Meinel A, Handzel R, Einenkel J: Histopathology of endometrial hyperplasia and endometrial carcinoma: an update. Ann Diagn Pathol 2007, 11:297-311
6. Lax SF: Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium. Pathology 2007, 39:46-54
7. Kelsey JL, LiVolsi VA, Holford TR, Fischer DB, Mostow ED, Schwartz PE, O'Connor T, White C: A case-control study of cancer of the endometrium. Am J Epidemiol 1982, 116:333-342
8. Gallup DG, Stock RJ: Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 1984, 64:417-420
9. Sherman ME: Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000, 13:295-308
10. Schneider HP: HRT and cancer risks. Maturitas 2002, 43 Suppl 1:S35-S52
11. Mindnich R, Moller G, Adamski J: The role of 17 beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 2004, 218:7-20
12. Lukacik P, Kavanagh KL, Oppermann U: Structure and function of human 17beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 2006, 248:61-71
13. Moeller G, Adamski J: Integrated view on 17beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 2009, 301:7-19
14. Peltoketo H, Luu-The V, Simard J, Adamski J: 17beta-hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes. J Mol Endocrinol 1999, 23:1-11
15. Poutanen M, Miettinen M, Vihko R: Differential estrogen substrate specificities for transiently expressed human placental 17 betahydroxysteroid dehydrogenase and an endogenous enzyme expressed in cultured COS-m6 cells. Endocrinology 1993, 133: 2639-2644
16. Husen B, Huhtinen K, Saloniemi T, Messinger J, Thole HH, Poutanen M: Human hydroxysteroid (17-beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts. Endocrinology 2006, 147:5333-5339
17. Saloniemi T, Lamminen T, Huhtinen K, Welsh M, Saunders P, Kujari H, Poutanen M: Activation of androgens by hydroxysteroid (17beta) dehydrogenase 1 in vivo as a cause of prenatal masculinization and ovarian benign serous cystadenomas. Mol Endocrinol 2007, 21:2627-2636
18. Lamminen T, Saloniemi T, Huhtinen K, Koskimies P, Messinger J, Husen B, Thole H, Poutanen M: In vivo mouse model for analysis of hydroxysteroid (17beta) dehydrogenase 1 inhibitors. Mol Cell Endocrinol 2009, 301:158-162
19. Saloniemi T, Welsh M, Lamminen T, Saunders P, Makela S, Streng T, Poutanen M: Human HSD17B1 expression masculinizes transgenic female mice. Mol Cell Endocrinol 2009, 301:163-168
20. Poutanen M, Isomaa V, Lehto VP, Vihko R: Immunological analysis of 17 beta-hydroxysteroid dehydrogenase in benign and malignant human breast tissue. Int J Cancer 1992, 50:386-390
21. Gunnarsson C, Jerevall PL, Hammar K, Olsson B, Nordenskjold B, Jansson A, Stal O: Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer. Breast Cancer Res Treat 2008, 108:35-41
22. Einspanier A, Lieder K, Bruns A, Husen B, Thole H, Simon C: Induction of endometriosis in the marmoset monkey (Callithrix jacchus). Mol Hum Reprod 2006, 12:291-299
23. Maentausta O, Sormunen R, Isomaa V, Lehto VP, Jouppila P, Vihko R: Immunohistochemical localization of 17 beta-hydroxysteroid dehydrogenase in the human endometrium during the menstrual cycle. Lab Invest 1991, 65:582-587
24. Maentausta O, Boman K, Isomaa V, Stendahl U, Backstrom T, Vihko R: Immunohistochemical study of the human 17 beta-hydroxysteroid dehydrogenase and steroid receptors in endometrial adenocarcinoma. Cancer 1992, 70:1551-1555
25. Martel C, Rheaume E, Takahashi M, Trudel C, Couet J, Luu-The V, Simard J, Labrie F: Distribution of 17 beta-hydroxysteroid dehydrogenase gene expression and activity in rat and human tissues. J Steroid Biochem Mol Biol 1992, 41:597-603
26. Miettinen MM, Mustonen MV, Poutanen MH, Isomaa VV, Vihko RK: Human 17 beta-hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic cell- and tissue-specific expression. Biochem J 1996, 314:839-845
27. Zeitoun K, Takayama K, Sasano H, Suzuki T, Moghrabi N, Andersson S, Johns A, Meng L, Putman M, Carr B, Bulun SE: Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol. J Clin Endocrinol Metab 1998, 83:4474-4480
28. Kasai T, Shozu M, Murakami K, Segawa T, Shinohara K, Nomura K, Inoue M: Increased expression of type I 17beta-hydroxysteroid dehydrogenase enhances in situ production of estradiol in uterine leiomyoma. J Clin Endocrinol Metab 2004, 89:5661-5668
29. Fechner S, Husen B, Thole H, Schmidt M, Gashaw I, Kimmig R, Winterhager E, Grummer R: Expression and regulation of estrogenconverting enzymes in ectopic human endometrial tissue. Fertil Steril 2007, 88:1029-1038
30. Marovitz W, Loucopoulos A, Satyaswaroop PG, Gurpide E, Todd R, Naftolin F: Apparent immunologic nonidentity of human placental and endometrial 17beta-estradiol dehydrogenase. Am J Obstet Gynecol 1980, 138:643-647
31. Casey ML, MacDonald PC, Andersson S: 17 beta-Hydroxysteroid dehydrogenase type 2: chromosomal assignment and progestin regulation of gene expression in human endometrium. J Clin Invest 1994, 94:2135-2141
32. Utsunomiya H, Suzuki T, Kaneko C, Takeyama J, Nakamura J, Kimura K, Yoshihama M, Harada N, Ito K, Konno R, Sato S, Okamura K, Sasano H: The analyses of 17beta-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma. J Clin Endocrinol Metab 2001, 86:3436-3443
33. Torn S, Nokelainen P, Kurkela R, Pulkka A, Menjivar M, Ghosh S, Coca-Prados M, Peltoketo H, Isomaa V, Vihko P: Production, purification, and functional analysis of recombinant human and mouse 17beta-hydroxysteroid dehydrogenase type 7. Biochem Biophys Res Commun 2003, 305:37-45
34. Ito K, Utsunomiya H, Suzuki T, Saitou S, Akahira J, Okamura K, Yaegashi N, Sasano H: 17Beta-hydroxysteroid dehydrogenases in human endometrium and its disorders. Mol Cell Endocrinol 2006, 248:136-140
35. Luu-The V, Tremblay P, Labrie F: Characterization of type 12 17beta-hydroxysteroid dehydrogenase, an isoform of type 3 17beta-hydroxysteroid dehydrogenase responsible for estradiol formation in women. Mol Endocrinol 2006, 20:437-443
36. Smuc T, Rizner TL: Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer. Mol Cell Endocrinol 2009, 301:74-82
37. Laplante Y, Cadot C, Fournier MA, Poirier D: Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: Blocking of ER(+) breast cancer cell proliferation induced by estrone. Bioorg Med Chem 2008, 16:1849-1860
38. Day JM, Foster PA, Tutill HJ, Parsons MF, Newman SP, Chander SK, Allan GM, Lawrence HR, Vicker N, Potter BV, Reed MJ, Purohit A: 17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer. Int J Cancer 2008, 122:1931-1940
39. Laplante Y, Rancourt C, Poirier D: Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors. Mol Cell Endocrinol 2009, 301:146-153
40. Weiss J, Zimmermann F: Tribromoethanol (Avertin) as an anaesthetic in mice. Lab Anim 1999, 33:192-193
41. Staley K, Scharfman H: A woman's prerogative. Nat Neurosci 2005, 8:697-699
42. Husen B, Huhtinen K, Poutanen M, Kangas L, Messinger J, Thole H: Evaluation of inhibitors for 17beta-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme. Mol Cell Endocrinol 2006, 248:109-113
43. Messinger J, Husen B, Koskimies P, Hirvela L, Kallio L, Saarenketo P, Thole H: Estrone C15 derivatives-a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors. Mol Cell Endocrinol 2009, 301:216-224
44. Vermeulen-Meiners C, Poortman J, Haspels AA, Thijssen JH: The endogenous concentration of estradiol and estrone in pathological human postmenopausal endometrium. J Steroid Biochem 1986, 24:1073-1078
45. Potischman N, Hoover RN, Brinton LA, Siiteri P, Dorgan JF, Swanson CA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD, Persky V, Lurain JR: Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 1996, 88:1127-1135
46. Berstein LM, Tchernobrovkina AE, Gamajunova VB, Kovalevskij AJ, Vasilyev DA, Chepik OF, Turkevitch EA, Tsyrlina EV, Maximov SJ, Ashrafian LA, Thijssen JH: Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer. J Cancer Res Clin Oncol 2003, 129:245-249
47. Graham JD, Clarke CL: Physiological action of progesterone in target tissues. Endocr Rev 1997, 18:502-519
48. Wheeler DT, Bristow RE, Kurman RJ: Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol 2007, 31:988-998
49. Beresford SA, Weiss NS, Voigt LF, McKnight B: Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997, 349:458 -461
50. Feeley KM, Wells M: Hormone replacement therapy and the endometrium. J Clin Pathol 2001, 54:435-440
51. Gunin AG, Kapitova IN, Suslonova NV: Effects of histone deacetylase inhibitors on estradiol-induced proliferation and hyperplasia formation in the mouse uterus. J Endocrinol 2005, 185:539-549
52. Couse JF, Korach KS: Contrasting phenotypes in reproductive tissues of female estrogen receptor null mice. Ann NY Acad Sci 2001, 948:1-8
53. Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery CA, Jr, Shyamala G, Conneely OM, O'Malley BW: Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 1995, 9:2266-2278
54. Nokelainen P, Puranen T, Peltoketo H, Orava M, Vihko P, Vihko R: Molecular cloning of mouse 17 beta-hydroxysteroid dehydrogenase type 1 and characterization of enzyme activity. Eur J Biochem 1996, 236:482-490
55. Pasqualini JR, Chetrite G, Blacker C, Feinstein MC, Delalonde L, Talbi M, Maloche C: Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in preand postmenopausal breast cancer patients. J Clin Endocrinol Metab 1996, 81:1460-1464
56. Miyoshi Y, Ando A, Shiba E, Taguchi T, Tamaki Y, Noguchi S: Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers. Int J Cancer 2001, 94:685-689
57. Shibuya R, Suzuki T, Miki Y, Yoshida K, Moriya T, Ono K, Akahira J, Ishida T, Hirakawa H, Evans DB, Sasano H: Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast. Endocr Relat Cancer 2008, 15:113-124
58. Goto T, Takano M, Albergaria A, Briese J, Pomeranz KM, Cloke B, Fusi L, Feroze-Zaidi F, Maywald N, Sajin M, Dina RE, Ishihara O, Takeda S, Lam EW, Bamberger AM, Ghaem-Maghami S, Brosens JJ: Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells. Oncogene 2008, 27:9-19
59. Robinson J: Prenatal programming of the female reproductive neuroendocrine system by androgens. Reproduction 2006, 132:539-547
60. Maentausta O, Peltoketo H, Isomaa V, Jouppila P, Vihko R: Immunological measurement of human 17 beta-hydroxysteroid dehydrogenase. J Steroid Biochem 1990, 36:673-680
61. Maentausta O, Menjivar M, Vihko R: Time-resolved immunofluorometric assay of 17 beta-hydroxysteroid dehydrogenase in plasma. Clin Chem 1991, 37:1412-1415
62. Utsunomiya H, Suzuki T, Ito K, Moriya T, Konno R, Sato S, Yaegashi N, Okamura K, Sasano H: The correlation between the response to progestogen treatment and the expression of progesterone receptor B and 17beta- hydroxysteroid dehydrogenase type 2 in human endometrial carcinoma. Clin Endocrinol (Oxf) 2003, 58:696-703
63. Rizner TL, Smuc T, Rupreht R, Sinkovec J, Penning TM: AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer. Mol Cell Endocrinol 2006, 248:126-135
64. Smuc T, Pucelj MR, Sinkovec J, Husen B, Thole H, Lanisnik Rizner T: Expression analysis of the genes involved in estradiol and progesterone action in human ovarian endometriosis. Gynecol Endocrinol 2007, 23:105-111
65. Leon L, Bacallao K, Gabler F, Romero C, Valladares L, Vega M: Activities of steroid metabolic enzymes in secretory endometria from untreated women with polycystic ovary syndrome. Steroids 2008, 73:88-95
66. Bacallao K, Leon L, Gabler F, Soto E, Romero C, Valladares L, Vega M: In situ estrogen metabolism in proliferative endometria from untreated women with polycystic ovarian syndrome with and without endometrial hyperplasia. J Steroid Biochem Mol Biol 2008, 110: 163-169
67. Delvoux B, Groothuis P, D'Hooghe T, Kyama C, Dunselman G, Romano A: Increased production of 17beta-estradiol in endometriosis lesions is the result of impaired metabolism. J Clin Endocrinol Metab 2009, 94:876-883
68. Delvoux B, Husen B, Aldenhoff Y, Koole L, Dunselman G, Thole H, Groothuis P: A sensitive HPLC method for the assessment of metabolic conversion of estrogens. J Steroid Biochem Mol Biol 2007, 104:246-251